Focus on agomelatine

Current Medical Research and Opinion

Volumn 27, Issue 4, 2011, Pages 745-749

  Green, Ben ^a  

^a Cheadle Royal Hospital   (United Kingdom)

Author keywords

Agomelatine; Antidepressant; Depression; Melatonin; Sleep

Indexed keywords

AGOMELATINE; CYPROHEPTADINE; LITHIUM SALT; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PLACEBO; SEROTONIN 2C RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROMIDE; VENLAFAXINE;

ANORGASMIA; ANXIETY DISORDER; BACKACHE; BEDTIME DOSAGE; BIPOLAR DISORDER; CONSTIPATION; DEPRESSION; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DYSPEPSIA; EJACULATION DISORDER; GASTROENTERITIS; HUMAN; HYPOMANIA; INFLUENZA; INSOMNIA; LIBIDO; LIVER DYSFUNCTION; MAJOR DEPRESSION; MANIA; MAXIMUM PLASMA CONCENTRATION; NECK PAIN; ORGASM DISORDER; PRESCRIPTION; REM SLEEP; REVIEW; RHINOPHARYNGITIS; SEASONAL AFFECTIVE DISORDER; SEXUAL DYSFUNCTION; SIDE EFFECT; SINUSITIS; SLOW WAVE SLEEP; SYSTEMATIC REVIEW; UPPER RESPIRATORY TRACT INFECTION; WITHDRAWAL SYNDROME;

ACETAMIDES; ADULT; ANIMALS; ANTIDEPRESSIVE AGENTS; ANXIETY; BIPOLAR DISORDER; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPNOTICS AND SEDATIVES; MODELS, BIOLOGICAL; SLEEP; TREATMENT OUTCOME;

EID: 79952681091     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.554534     Document Type: Review

References (20)

1. Stein D, Ahokas A, De Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008;28:561-6
2. Quera Salva M-A, Vanier B, Laredo J, et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol 2007;10:691-6 (Pubitemid 47517524)
3. Pjrek E, Winkler D, Konstantinidis A, et al. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology 2007;190:575-9 (Pubitemid 46204474)
4. Turek FW, Gillette MU. Melatonin, sleep and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med 2004;5:523-32 (Pubitemid 39420030)
5. Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine (2C) receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003;306:954-64
6. Hardeland R, Poeggler B, Srinivasan V, et al. (2008) Melatonergic drugs in clinical practice. Arzneimittel-Forschung (Drug Research) 2008;58:1-10 (Pubitemid 351220148)
7. Kennedy SH, Rizvi S, Fulton K, et al. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008;28:329-33
8. 2c antagoniostic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007;10:661-73
9. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
10. Kennedy SH, Elmsley R. Placebo controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2005;16:93-100
11. Stahl SM, Fava M, Trivedi MH, et al. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry 2010;71:616-26
12. Kasper S, Hajak G, Wulff K, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest - activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry 2010;71:109-20
13. Goodwin GM, Emsley R, Rembry S, Rouillon F; Agomelatine Study Group. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:1128-37
14. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007;68:1723-32 (Pubitemid 350247502)
15. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-5
16. Calabrese JR, Guelfi JD, Perdrizet-Chevallier C. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disorders 2007;9:628-35 (Pubitemid 47365631)
17. European Public Assessment Report (EPAR) for Valdoxan. Available at: http://www.emea.europa.eu [Last accessed 9 December 2010]
18. Montgomery S. Major depressive disorders: clinical efficacy and tolerability of agomelatine, a new melatonergic agonist. Eur Neuropsychopharmacol 2006;16:S633-S638 (Pubitemid 44528982)
19. Montejo AL, Prieto N, Terleira A, et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQSALSEX scale. J Psychopharmacol 2010;24:111-20
20. Hardeland R. New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatonergic agonists. Neuropsychiatr Dis Treat 2009;5:341-54